Core Insights - Medidata and CTI have expanded their 12-year partnership to enhance patient-centric research and innovation in clinical trials [1][4] - The collaboration focuses on integrating Medidata eCOA, which improves data collection capabilities and enhances the clinical trial experience for patients [2][3] Company Overview - Medidata is a leading provider of clinical trial solutions, celebrating 25 years of innovation across over 36,000 trials and 11 million patients [6] - CTI is a global leader in research services, specializing in a wide range of therapeutic areas and recognized as one of the 20 largest contract research organizations [8][9] Technological Advancements - The Medidata Patient Experience offers an AI-powered technology solution that supports every stage of the clinical trial journey, from recruitment to study completion [5] - Medidata eCOA has been recognized as a leader in the Everest Group's PEAK Matrix® Assessment for eCOA, highlighting its effectiveness in improving patient engagement and data integrity [4]

Core Insights - Medidata has announced significant advancements to its electronic informed consent technology, Medidata Consent, aimed at enhancing patient enrollment and streamlining the clinical trial process [1][2] Group 1: Product Features and Enhancements - The updated Medidata Consent solution focuses on adaptability, usability, and global compliance, addressing the need for a simpler and more flexible consent management process [2] - Key features include AI-assisted setup that reduces manual effort by up to 75%, an intuitive user experience for both patients and site staff, and seamless integration with the broader Medidata platform [6] - Future enhancements will allow remote registration for participants and provide personalized educational content to improve understanding of the study process [3] Group 2: Company Background and Market Position - Medidata has been a leader in clinical trial solutions for 25 years, supporting over 36,000 trials and 11 million patients, with more than 1 million registered users across approximately 2,300 customers [4] - The company is recognized for its technological innovation and has been acknowledged as a Leader by Everest Group and IDC [4]

Core Insights - Medidata has extended its collaboration with Sanofi to enhance clinical research and patient care through improved processes and data management [1][4] - The partnership aims to leverage Medidata's AI-embedded platform solutions to streamline clinical workflows and reduce costs and delays in drug development [2][4] Company Overview - Medidata is a leading provider of clinical trial solutions, celebrating 25 years of innovation with over 36,000 trials and 11 million patients involved [5] - The company offers a comprehensive platform that integrates analytics-powered insights and has over 1 million registered users across approximately 2,300 customers [5] Collaboration Details - Sanofi will utilize Medidata's expertise in decentralized clinical trials, receiving consulting and operational support as part of the extended agreement [3] - The collaboration focuses on enhancing data quality, improving study design, and accelerating the clinical development process [4]

Core Viewpoint - Dassault Systèmes is currently in a "show me" phase, indicating a lack of immediate catalysts for stock movement, leading to a hold rating on the stock [1] Company Analysis - The company has been previously analyzed with a hold rating due to the absence of near-term catalysts [1] - The investment approach taken includes fundamental, technical, and momentum investing, suggesting a comprehensive analysis of the company's performance [1] Investor Perspective - The individual investor managing their own capital emphasizes the importance of various investment strategies, indicating a diversified approach to investment [1] - The purpose of writing on Seeking Alpha is to track investment ideas and connect with like-minded investors, highlighting the community aspect of investment discussions [1]

Core Insights - Medidata has extended its collaboration with Sanofi to enhance clinical research processes and patient care through the use of Medidata's Patient, Data, and Study Experiences [1][2] - The partnership aims to streamline clinical workflows, reduce costs, and improve the quality of clinical trials by integrating AI-embedded solutions [2][4] - Sanofi will utilize Medidata's expertise in decentralized clinical trials, receiving consulting and operational support as part of the agreement [3][4] Company Overview - Medidata has been a leader in clinical trial solutions for 25 years, supporting over 36,000 trials and 11 million patients, with a robust platform trusted by more than 1 million users [5] - The company is recognized for its technological innovation and has been acknowledged as a Leader by Everest Group and IDC [5] - Medidata is a brand under Dassault Systèmes, which has a broad customer base of 370,000 across various industries [6]

Core Insights - Medidata and Sanofi have expanded their partnership to enhance clinical research, focusing on innovation, speed to market for new therapies, and improved health outcomes globally [1][3] - The collaboration will utilize Medidata's AI-embedded platform solutions to unify clinical workflows, reduce costs, and improve trial processes [2][4] Company Overview - Medidata has been a leader in clinical trial solutions for 25 years, supporting over 36,000 trials and 11 million patients, with a user base exceeding 1 million across approximately 2,300 customers [5] - Sanofi is a global healthcare company dedicated to transforming medicine and providing life-changing treatments and vaccines to millions [7] Partnership Details - The new agreement will leverage Medidata's expertise in decentralized clinical trials and provide Sanofi with strategic consulting and operational support to streamline research processes [3][4] - The partnership aims to enhance data quality, improve study design, and elevate patient care through unified solutions tailored to Sanofi's needs [4]

Core Insights - Dassault Systèmes reported solid third-quarter results for 2025, showcasing strong operational performance and reaffirming full-year EPS growth on adjusted revenue outlook [2][3][4] Financial Performance - Total revenue for Q3 2025 increased by 5% to €1.46 billion, with software revenue also up by 5% [9][16] - Recurring revenue rose by 9%, driven by a 16% increase in subscription revenue [9][10] - Non-IFRS operating margin improved to 30.1%, up 100 basis points compared to the previous year [8][9] - Non-IFRS diluted EPS grew by 10% to €0.29 for the quarter [9][10] Revenue Breakdown - Industrial Innovation software revenue increased by 9% to €717 million, representing 55% of total software revenue [15][16] - Life Sciences software revenue decreased by 3% to €257 million, accounting for 20% of software revenue [17] - Mainstream Innovation software revenue rose by 4% to €341 million, representing 26% of software revenue [17] Geographic Performance - Revenue from the Americas grew by 7%, contributing 41% of software revenue [16] - European revenue increased by 4%, representing 36% of software revenue, with strong performance in France and Germany [16] - Asia's revenue rose by 4%, led by growth in India and Korea, accounting for 22% of software revenue [16] Strategic Initiatives - The company emphasized its commitment to AI integration within its 3DEXPERIENCE platform, highlighting innovative solutions like Virtual Twin as a Service [6][7] - The shift towards subscription models is gaining momentum, with recurring revenue now accounting for 84% of software revenue year-to-date [10][11] Future Outlook - The company adjusted its full-year revenue growth outlook to 4-6%, down from the previous 6-8% [9][12] - The diluted EPS target for the full year remains at 7-10% growth [12][19]

Core Insights - Sanofi and Medidata have expanded their partnership to enhance clinical research and expedite the development of new therapies, focusing on improving patient journeys and operational efficiency [1][3] - The collaboration will utilize Medidata's AI-embedded platform solutions to unify clinical workflows, reduce costs, and accelerate the delivery of innovative treatments [2][4] Company Overview - Medidata has been a leader in providing clinical trial solutions for over 25 years, supporting more than 36,000 trials and 11 million patients, and is recognized for its technological innovation and extensive clinical trial data [5] - Sanofi is a global healthcare company dedicated to improving lives through innovative treatments and vaccines, emphasizing sustainability and social responsibility in its operations [7]

Core Insights - Oakmark Global Fund underperformed the MSCI World Index in the third quarter [1] Fund Activity - The fund initiated new positions in Salesforce, Dassault Systèmes, Hexagon, and Targa Resources during the quarter [1] - The fund exited positions in Amazon.com, Centene, and St. James's Place [1]

Core Insights - The Fund underperformed the MSCI World ex USA Index for the quarter but has outperformed the benchmark since inception [5] - Consumer discretionary and materials sectors were the largest contributors to performance, while industrials and communication services were the largest detractors [5] - Geographically, the portfolio is heavily weighted towards Europe ex U.K. (68.4%), followed by the U.K. (11.5%) and Asia ex Japan (9.3%) [5] Performance Analysis - Kering was the top contributor during the quarter, driven by leadership changes and improving revenue trends [7] - CNH Industrial was the top detractor, facing weak results and soft demand, particularly in the U.S., but management expects a rebound in 2025 [8] Portfolio Activity - Six new positions were added to the Fund, while nine were exited during the quarter [9] - New purchases included Bunzl, which is expected to return to stable growth despite recent execution issues [10] - Dassault Systèmes, a leader in virtual twin technology, is viewed as a high-quality investment opportunity despite a nearly 40% decline in share price [11] Company Highlights - FEMSA, a diversified Latin American conglomerate, is well-positioned for growth through strategic divestments and share buybacks [12] - Hexagon has upgraded its management team and is expected to see improvements in return on capital employed and cash flow [13] - Siemens Healthineers is positioned for profitable growth in medical technology, with a favorable product cycle and turnaround in its diagnostics business [16] Investment Returns - The Fund's average annualized total returns show strong performance across various time frames, with the Institutional Class returning 26.51% year-to-date [18]